BlueRock Therapeutics

BlueRock Therapeutics is an engineered cell therapy company that develops regenerative medicines for intractable diseases. BlueRock's CELL+GENE platform is used to direct cellular differentiation and genetically engineer cells to create a new generation of cellular medicines in the areas of neurology, cardiology, and immunology.

TypeSubsidiary
Parent CompanyBayer
HQCambridge, MA, US
Founded2016
Websitebluerocktx.com
Cybersecurity ratingCMore
BlueRock Therapeutics was founded in 2016 and is headquartered in Cambridge, MA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at BlueRock Therapeutics

Emile Nuwaysir

Emile Nuwaysir

President and CEO, Board Member
Stefan Oelrich

Stefan Oelrich

President, Pharmaceuticals Division
Seth Ettenberg

Seth Ettenberg

Chief Scientific Officer
Joachim Fruebis

Joachim Fruebis

Chief Development Officer
Ainslie Little

Ainslie Little

SVP, Corporate Strategy
Show more

BlueRock Therapeutics Office Locations

BlueRock Therapeutics has offices in Cambridge, New York and Toronto
Cambridge, MA, US (HQ)
1 Broadway
New York, NY, US
36 E 31st Street, Suite 602
New York, NY, US
450 E 29th St #504
Toronto, CA
101 College Street, East Tower
Show all (4)

BlueRock Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

Total Funding

$225 m

Investors

In total, BlueRock Therapeutics had raised $225 m. BlueRock Therapeutics is a subsidiary of Bayer

BlueRock Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

BlueRock Therapeutics Online and Social Media Presence

Embed Graph

BlueRock Therapeutics News and Updates

Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine

- Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials - - Collaboration combines BlueRock’s leading induced pluripote…

BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease

CAMBRIDGE, Mass., Jan. 7, 2021 /PRNewswire/ -- BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA)...

BlueRock Therapeutics Frequently Asked Questions

  • When was BlueRock Therapeutics founded?

    BlueRock Therapeutics was founded in 2016.

  • Who are BlueRock Therapeutics key executives?

    BlueRock Therapeutics's key executives are Emile Nuwaysir, Stefan Oelrich and Seth Ettenberg.

  • How many employees does BlueRock Therapeutics have?

    BlueRock Therapeutics has 200 employees.

  • Who are BlueRock Therapeutics competitors?

    Competitors of BlueRock Therapeutics include ACADIA Pharmaceuticals, Sangamo Therapeutics and Regenxbio.

  • Where is BlueRock Therapeutics headquarters?

    BlueRock Therapeutics headquarters is located at 1 Broadway, Cambridge.

  • Where are BlueRock Therapeutics offices?

    BlueRock Therapeutics has offices in Cambridge, New York and Toronto.

  • How many offices does BlueRock Therapeutics have?

    BlueRock Therapeutics has 4 offices.